Last reviewed · How we verify
Onon (PRANLUKAST)
Onon (PRANLUKAST) is a small molecule drug that targets the cysteinyl leukotriene receptor 1. It is used to treat allergic rhinitis and asthma by blocking the action of leukotrienes, which are chemical messengers involved in inflammation. The commercial status of Onon is not specified, but it is a pranlukast drug class. Key safety considerations are not provided. Onon is used to alleviate symptoms of allergic rhinitis and asthma.
At a glance
| Generic name | PRANLUKAST |
|---|---|
| Drug class | pranlukast |
| Target | Cysteinyl leukotriene receptor 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1995 |
Approved indications
- Allergic rhinitis
- Asthma
Common side effects
Key clinical trials
- Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers (PHASE1)
- An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327) (PHASE3)
- Safety, Pharmacokinetic Study of PRIC in Healthy Adult Subjects (PHASE1)
- Study of ONO-1078 in Patients With Chronic Sinusitis (PHASE3)
- Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Onon CI brief — competitive landscape report
- Onon updates RSS · CI watch RSS